Compare Standard Lithium Ltd (SLI) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Standard Lithium Ltd vs Twist Bioscience Corp — how do they compare? Standard Lithium Ltd trades at $2.37 (market cap $589.88M), while Twist Bioscience Corp trades at $125.52 (market cap $8.42B). The key difference: Twist Bioscience Corp is far larger — about 14.3× Standard Lithium Ltd's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Standard Lithium Ltd nearer its low. Which is the better fit depends on your goals.
| SLI | TWST | |
|---|---|---|
Market Cap | $589.88M | $8.42B |
Sector | Basic Materials | Health |
52-Week High | $5.65 | $153.10 |
52-Week Low | $1.93 | $24.16 |
Enterprise Value | $452.79M | $8.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Standard Lithium (SLI) trades at $2.40, down 0.83% today, with a bullish technical signal despite negative profitability metrics. The company shows progress with recent DOE clearance and key customer agreements, including LG Energy Solution, while maintaining 100% analyst buy ratings. Cash flow remains positive primarily from financing activities, though operational cash flow is negative as the company invests heavily in lithium project development.
The outlook hinges on successful project execution and Final Investment Decision for the Arkansas lithium project, which could unlock $250 million in government funding. Key risks include execution delays and negative profitability, but strong institutional interest and supportive government policies for critical minerals provide upside potential for patient investors.
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
